Q BioMed Inc. (QBIO) Research

Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets liver cancer. The company also collaborates with Mannin Research Inc. on the development of treatments for conditions such as acute respiratory distress syndrome, glaucoma, and various kidney diseases. Incorporated in New York, New York, in 2013, the entity was initially named ISMO Tech Solutions, Inc. before adopting its current name, Q BioMed Inc., in July 2015.

Market snapshot

Symbol
QBIO
Price
$0.00
Day change
-0.00%
Market cap
$14.5K
P/E ratio
-0.00x
52-week range
0.000099999997-0.02505
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • NanoLogix, Inc. (NNLX)
  • Strategic Partners A/S (OZYMF)
  • Poniard Pharmaceuticals, Inc. (PARD)
  • PaxMedica, Inc. Common Stock (PXMD)
  • RenovaCare, Inc. (RCAR)
  • Regenicin, Inc. (RGIN)
  • Scopus BioPharma Inc. (SCPS)
  • Vaxxinity, Inc. (VAXX)

Recent insider activity

  • Corin Denis — A-Award (200000 shares) on 2022-05-26
  • Rosenstadt William S — A-Award (35000 shares) on 2021-02-01
  • Corin Denis — A-Award (500000 shares) on 2020-10-27
  • Corin Denis — A-Award (150000 shares) on 2020-08-29
  • Corin Denis — A-Award (150000 shares) on 2020-08-29

Open Q BioMed Inc. (QBIO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.